EGFR-mutated pulmonary adenocarcinoma with concurrent PIK3CA mutation, and with acquired RET fusion and EGFR T790M mutation after afatinib therapy

Similar Items

• Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib
  by: Yuko Oya, et al.
  Published: (2021-01-01)
• The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy
  by: Cheng WC, et al.
  Published: (2021-01-01)
• Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma.
  by: Kang-Yi Su, et al.
  Published: (2018-01-01)
• Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations
  by: Bin Zou, et al.
  Published: (2017-07-01)
• A case report of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with T790M mutation and epithelial-to-mesenchymal transition
  by: Nana Zhang, et al.
  Published: (2017-01-01)